Long-Term Administration of Oral Low-Dose Topoisomerase II Inhibitors, MST-16 and VP-16, for Refractory or Relapsed Non-Hodgkin’s Lymphoma

Publisher： Karger

E-ISSN： 1421-9662|104|2-3|128-130

ISSN： 0001-5792

Source： Acta Haematologica, Vol.104, Iss.2-3, 2001-01, pp. : 128-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite

Two Oral Trofosfamide Schedules in Elderly Patients with Refractory Non-Hodgkin‘s Lymphoma

By  

Oncology Research and Treatment, Vol. 22, Iss. 2, 1999-05 ,pp. : 134-138

Karger

Access to resources Recommend Favorite

Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 970-974

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antibody Therapy with Rituximab for Patients with Low-Grade Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 22, Iss. 3, 1999-07 ,pp. : 184-190

Karger

Access to resources Recommend Favorite

Primary Non-Hodgkin’s Lymphoma of Urinary Bladder

By  

Urologia Internationalis, Vol. 72, Iss. 1, 2004-01 ,pp. : 82-84

Karger

Access to resources Recommend Favorite